Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator agent with beta-adrenergic agonist activity. It is thought to cause relaxation of vascular smooth muscle, leading to vasodilation.
## Primary Indications
* Treatment of peripheral vascular diseases (e.g., atherosclerosis obliterans, thromboangiitis obliterans, Raynaud's disease, intermittent claudication).
* Adjunctive therapy in cerebrovascular insufficiency.
## Adult Dosing
* **Oral:** 10 mg to 20 mg three to four times daily.
* The optimal dose may vary based on individual response and clinical judgment.
* Maximum dose is generally not explicitly stated, but 80 mg daily is a common upper limit.
## Pediatric Dosing
There is no established pediatric dosing for isoxsuprine hydrochloride.
## Dose Adjustments
* **Hepatic Impairment:** No specific guidelines, but caution is advised as the drug is metabolized in the liver.
* **Renal Impairment:** No specific guidelines, but caution is advised.
## Contraindications
* **Hypersensitivity** to isoxsuprine hydrochloride.
* **Gastrointestinal hemorrhage** or **ileus** (due to potential decrease in gastrointestinal motility).
* **Bradycardia**.
* **Hypotension**.
* **Use immediately postpartum** or in patients with **congenital heart defects** due to potential for paradoxical adverse effects.
## Adverse Effects
* **Cardiovascular:** Hypotension, flushing, tachycardia, dizziness, lightheadedness, arrhythmias.
* **Gastrointestinal:** Nausea, vomiting, abdominal distress, drowsiness.
* **Other:** Weakness, nervousness, blurred vision, rash.
## Key Drug Interactions
* **Antihypertensives:** May potentiate hypotensive effects.
* **Epinephrine:** May antagonize the vasodilating effects of isoxsuprine.
* **Drugs that prolong QT interval:** Potential for additive effects on QT interval; use with caution.
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease improvement.
* Adverse effects.
## Clinical Pearls
* Effectiveness in the treatment of peripheral vascular disease is controversial and not well-established by rigorous clinical trials.
* May cause drowsiness; patients should be cautioned about driving or operating machinery.
* Onset of action may be delayed; sustained use is often required to assess efficacy.
***
*Disclaimer: This information is intended for healthcare professionals. Always verify current prescribing information and local protocols before making treatment decisions.*
